国外药物经济学评价在我国政策决策中的借鉴研究被引量：8

Benchmarking Study of Abroad Pharmacoeconomic Evaluation in the Policy Decisions

下载PDF

导出

摘要目的:根据药物经济学评价应用的国际经验,以苏格兰、澳大利亚、英国和美国政策决策路径为例,结合我国现状,提出药物经济学评价在我国政策决策中的应用建议。方法:文献研究法,以中国知网和国内外医药卫生官方网站为数据源,对药物经济学评价在政策决策领域应用的文献资料进行总结与分析。结果和结论:提出我国应用药物经济学的政策决策思路。 Objective：According to international experience of applications of pharmacoeconomic evaluation, taking the policy-making paths of Scotland, Australia, the UK and the U.S.for example, combining with status in our country, make suggestions for pharmacoeconomic application in our policy-making process.Methods：Choosing the CNKI library and domestic and international medical and health official website as the data source, summarize and analyze literature relevant to pharmacoeconomic evaluation in the policy decision-making field.Results ＆amp; Conclusion： To put forward policy-making ideas for pharmacoeconomic application in our country.

作者刘芳黄少军石元元朱文涛

机构地区北京中医药大学管理学院内蒙古林业总医院药剂科

出处《中国药物评价》 2014年第3期184-188,共5页 Chinese Journal of Drug Evaluation

关键词药物经济学评价政策决策 Pharmacoeconomic evaluation Policy decisions

分类号 R95 [医药卫生—药学]

引文网络
相关文献

参考文献13

1杨莉,胡善联,宫印成.药物经济学评价在卫生决策中的国际应用[J].中国药房,2004,15(6):347-350. 被引量：34
2Eldessouki R, Smith MD. Heahh Care System Information Sharing: A Step Toward Better Health Globally[J]. Value Health Regional Issues, 2012,1 : 118-129.
3International Society for Phannacoeconomics and Outcomes Research, ISPOR Phamacoeconomic Guidelines Around The World[EB/OL], [2014-03-24]. http://www, ispor, org/PEguidelines/index.asp.
4International Society for Phamacoeconomics and Outcomes Research. IS- POR Global Health Care Systems Road Map[ EB/OL]. [2014-0r3-24 ]. ht- tp://www, ispor, org/HTARoadMaps/Default, asp.
5International Society for Phannacoeconomics and Outcomes Research. Scot- land-Reimbursement Process [ EB/OL]. [ 2014-03-24] http://www, is- pot. org/HTARoadMaps/Scotland, asp.
6Scotland Medicines Consortium. Working with SMC-A Guide for Manufac- tures[EB/OL]. [2014-03-24]. http://www, scottishmedicines, org. uk.
7龚向光,胡善联.澳大利亚药物经济学评价指南介绍[J].卫生经济研究,2002,19(6):21-23. 被引量：13
8Australian Government: Department of Health. The Listing Steps [EB/OL ]. [2014-03-24]. bttp://www, pbs. gov. au/info/industry/listing/listing-steps.
9National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 [ EB/OL]. [ 2014-03-24]. http://www, nice. org. uk/media/D45/1E/GuideToMethodsTechnologyAppraisa12013, pdf.
10Centers For Disease Control and Prevention. Economics and Public Health at CDC[EB/OL]. [2014-03-24]. http://www. cdc. gov/mmwr/preview/ mmwrhtml/su5502a7.html.

二级参考文献18

1陈英耀.OECD国家卫生费用和卫生服务的趋势[J].中国卫生资源,2001,4(3):141-144. 被引量：10
2Drummond,MF.The role of economic evaluation in the pricing and reimbursement of medicines[J] .Health Policy, 1997,40:199.
3Ministry of health, welfare and sports. The Future of Health Insurance System [ S ]. Dutch, 1999.
4Ziekenfondsraad.Dutch Guidelines for Pharmacoeconomic Research [ S]. Ziekenfondsraad amst elveen, March,1999.
5Tobin H,Tumer N,Wyatt G.Pharmacoeconomics 2002:A Concise Guide [ S ]. PPR Communications, Ltd., Cambridge, UK. 2002.
6Torrance G.Current experience with guidelines for economic evaluation in Canada[J ]. Drug Information Journal, 1996,30: 507.
7Glennie JL,Torrance GW,Baladi JF,et al .The revised Canadian guidelines for the economic evaluation of pharmaceuticals [ J ] . Pharmacoeconom ics, 1999,15(5): 459.
8Anis AH,Gagnon Y.Using economic evaluations to make formulary coverage decisions: so much for guidelines[J]. Pharmacoeconomics, 2000,18(1): 55.
9Kanavos P.Pharmaceutical Pricing and Reimbursement in Europe- 2002[ S ].PJB Publications Ltd. 2002.
10National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal [S] .March,2001